DEVELOPMENT OF ENZYME-LINKED IMMUNOSORBENT ASSAYS (ELISAS) FOR NINDS NIH BLUEPRINT NEUROTHERAPEUTICS (BPN) BIOLOGICS PROJECT

为 NINDS NIH 蓝图神经治疗 (BPN) 生物制品项目开发酶联免疫吸附测定 (ELISA)

• 批准号: 10948209
• 负责人: AMANDA BURNAUGH
• 金额: $ 39.44万
• 依托单位: BATTELLE CENTERS/PUB HLTH RES & EVALUATN
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-02-07 至 2028-02-06
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10948209
• 关键词: DEVELOPMENT; ENZYME; LINKED; IMMUNOSORBENT; ASSAYS

The National Institute of Neurological Disorders and Stroke (NINDS), via its Blueprint (BPNBiologics) network, is funding a cooperative agreement for the development of an antibody for treatment of Duchenne’s muscular dystrophy (DMD). The goals of the BPN-Biologics cooperative agreement are to optimize the lead antibody, evaluate short-term in vivo efficacy of the optimized lead antibody(ies), complete pre-clinical studies and manufacturing, and progress the lead clinical candidate antibody(ies) through IND-enabling studies and an IND regulatory filing. A single down-selected lead progeny antibody with optimal characteristics will then progress to IND-enabling in vivo and in vitro studies and to clinical trial evaluation.

国家神经系统疾病与中风研究所（NINDS），通过其蓝图（BPNBIologics） 网络，正在为开发抗体的合作协议提供资金 用于治疗Duchenne的肌肉 营养不良（DMD）。 BPN生物学合作协议的目标是优化 铅抗体，评估优化铅的短期体内效率 抗体（IES），完整的临床前研究和制造，并进行铅临床 候选抗体（IES）通过辅助研究和IND调节归档。一个 然后，具有最佳特性的下选择铅后代抗体将 进展到体内和体外研究和临床试验评估的进展。